Special Offers & Promotions



Latest News



View Channel

New Products



View Channel

Video Presentations



View Channel

Separation Science



View Channel

Microscopy & Image Analysis



View Channel

Laboratory Automation & IT Solutions



View Channel


New Application Note: COVID-19 agent molnupiravir

publication date: Sep 20, 2022
author/source: YMC Europe GmbH



Molnupiravir (Lagevrio®) is an antiviral medication to treat mild to medium COVID-19 infection.

Molnupiravir is actually a prodrug of the active substrate N4-hydroxycytidine (NHC), a synthetic ribonucleoside analogue. The treatment leads to the introduction of copying errors during viral RNA replication and by this inhibits the viral reproduction.
This new Application Note demonstrates how molnupiravir and its active agent β-d-N4-hydroxycytidine can be separated by using a YMC-Triart C18 UHPLC column and a MS compatible mobile phase at pH 4.3 and relatively mild temperature of 40°C.


View Application Note

Recent news from YMC


If you have not logged into the website then please enter your details below.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month



Today's Picks



Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners


Exhibitions & Events